Team:CU-Boulder/Project

From 2014.igem.org

(Difference between revisions)
 
(9 intermediate revisions not shown)
Line 1: Line 1:
-
{{CU-Boulder-header}}
+
{{Template:UCB-Main}}
-
{{:Team:CU-Boulder/Menu}}
+
{{Template:UCB-NavBar}}
-
{{:Team:CU-Boulder/PageBasic}}
+
==Our Project==
 +
<br>
 +
In the last decade the number of antibiotic resistant bacteria has grown at a shocking rate, making these “superbugs” one of our top global health threats. This trend indicates that the golden age of antibiotics is ending and makes the search for new antibacterial treatments more important than ever. New bacterial treatments need the ability to adapt faster than the harmful bacteria that they target. Additionally, new treatments must preserve essential bacteria of the microbiome and specifically target pathogenic bacteria in a mixed population.
-
<!--main content -->
+
New technology has recently emerged that allows us to achieve these goals.
-
<table width="70%" align="center">
+
CRISPR-Cas9 consists of an endonuclease (Cas9) that is guided to a specific sequence within a genome by a CRISPR RNA component. Once targeted to the genome, Cas9 causes a double stranded break, killing the host bacterial cell. Because the killing relies on the sequence of the CRISPR guide RNA, which can be engineered to contain a short specific nucleotide sequence, unique genes within any pathogenic bacteria can be targeted.
-
<!--Project content  -->
+
Utilizing a non-replicating phage as a vector, we can efectively deliver the CRISPR-Cas9 machinery to cells and kill bacteria through CRISPR-Cas9–targeting of the genome. Ongoing experiments are aimed at demonstrating that sequence-specific killing can occur in a mixed population of cells as well as in an in vivo model. We believe that this technology, which we refer to as “Pathogen Assassin” will have broad applications ranging from medicine to industry and beyond.
-
<tr><td > <h3> Project Description </h3></td>
+
-
<td ></td >
+
-
<td > <h3> Content</h3></td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
<td width="45%"  valign="top">
+
-
<p>Tell us more about your project.  Give us background. Use this as the abstract of your project. Be descriptive but concise (1-2 paragraphs) </p>
+
<br>
<br>
-
<h3>References </h3>
+
<br>
-
<p>
+
<br>
-
iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you though about your project and what works inspired you. </p>  
+
<br>
-
</td>
+
{{Template:UCB-Footer}}
-
 
+
-
<td></td>
+
-
<td  width="45%"  valign="top">
+
-
<p> You can use these subtopics to further explain your project</p>
+
-
 
+
-
<ol>
+
-
<li>Overall project summary</li>
+
-
<li>Project Details</li>
+
-
<li>Materials and Methods</li>
+
-
<li>The Experiments</li>
+
-
<li>Results</li>
+
-
<li>Data analysis</li>
+
-
<li>Conclusions</li>
+
-
</ol>
+
-
 
+
-
<p>
+
-
It's important for teams to describe all the creativity that goes into an iGEM project, along with all the great ideas your team will come up with over the course of your work.
+
-
</p>
+
-
 
+
-
<p>
+
-
It's also important to clearly describe your achievements so that judges will know what you tried to do and where you succeeded. Please write your project page such that what you achieved is easy to distinguish from what you attempted.
+
-
</p>
+
-
 
+
-
</td>
+
-
 
+
-
</tr>
+
-
 
+
-
 
+
-
</table>
+
-
</html>
+

Latest revision as of 17:39, 14 October 2014

Our Project


In the last decade the number of antibiotic resistant bacteria has grown at a shocking rate, making these “superbugs” one of our top global health threats. This trend indicates that the golden age of antibiotics is ending and makes the search for new antibacterial treatments more important than ever. New bacterial treatments need the ability to adapt faster than the harmful bacteria that they target. Additionally, new treatments must preserve essential bacteria of the microbiome and specifically target pathogenic bacteria in a mixed population.

New technology has recently emerged that allows us to achieve these goals. CRISPR-Cas9 consists of an endonuclease (Cas9) that is guided to a specific sequence within a genome by a CRISPR RNA component. Once targeted to the genome, Cas9 causes a double stranded break, killing the host bacterial cell. Because the killing relies on the sequence of the CRISPR guide RNA, which can be engineered to contain a short specific nucleotide sequence, unique genes within any pathogenic bacteria can be targeted.

Utilizing a non-replicating phage as a vector, we can efectively deliver the CRISPR-Cas9 machinery to cells and kill bacteria through CRISPR-Cas9–targeting of the genome. Ongoing experiments are aimed at demonstrating that sequence-specific killing can occur in a mixed population of cells as well as in an in vivo model. We believe that this technology, which we refer to as “Pathogen Assassin” will have broad applications ranging from medicine to industry and beyond.




Retrieved from "http://2014.igem.org/Team:CU-Boulder/Project"